Status:  Clearance

Acquirer:  Shanghai RAAS Blood Products Co., Ltd (China)

Acquired:  Grifols Diagnostic Solutions Inc. (U.S.)

Value:  US$1.9 billion

Industry:  Healthcare

Electronic e-healthcareOn March 7, 2019, Grifols S.A., a Spanish pharmaceutical and chemical company that is a leading producer of blood plasma-based products, entered into a purchase agreement to acquire Shanghai RAAS Blood Products Co., Ltd., which was subject to CFIUS clearance (See Section 4.1.7., Agreement for Assets Purchase by Share Issue, Grifos S.A. Form 20-F, Ex-4.5,  Apr. 5, 2019, SEC Filing.)  Under the transaction, Grifols S.A. “will acquire 26.2% of the voting and economic rights in Shanghai RAAS in exchange for a contribution of 45% of the economic rights and 40% of the voting rights in [Grifols’] U.S. subsidiary, Grifols Diagnostic Solutions Inc.” (Grifols S.A. Form 20-F, Apr. 5, 2019, SEC Filing.)  On September 30, 2019, “Grifols obtained the authorization from the Committee on Foreign Investment in the United States (CFIUS) to complete the transaction.” (Grifols S.A. Form 6-K, Nov. 13, 2019, SEC Filing; see Grifols S.A. Press Release, Grifols and Shanghai RAAS obtain authorization for their strategic alliance in China, November 13, 2019.)

Please contact us with any questions.